Moscow Institute of Physics and Technology Partners with BiOptix in Development of Novel Chip to Increase SPR Sensitivity

New graphene oxide biosensor chip may significantly accelerate drug development

Boulder, Colo. — Nov. 3, 2015 — BiOptix, a life science tools company that provides an affordable and powerful solution for drug discovery scientists that require label-free, real-time detection of biomolecular interactions, today announced that the BiOptix SPR biosensor contributed to the design of a novel, highly sensitive new graphene oxide (GO) biosensor chip developed by the Moscow Institute of Physics and Technology (MIPT).


The properties of the GO-based sensor chip result in higher sensitivity and reduced signal-to-noise ratio, which in the future may speed up the development of new drugs and vaccines for diseases like HIV, hepatitis and cancer. Yury Stebunov, a scientist at the MIPT, led the research and consulted BiOptix scientists for expert technical assistance and guidance in the experiment. The results were published in the ACS Applied Materials & Interfaces.


“We have been active users of the instrument for the last four years,” said Stebunov. “Many years of experience with the BiOptix SPR instrument confirm its benefits and it was the best choice for our research.”


Stebunov and the team from the Laboratory of Nanooptics and Plasmonics at MIPT created and patented a novel type of surface plasmon resonance (SPR) sensor chip with the linking layer, made of GO, a material with more attractive optical and chemical properties than pristine graphene. The new chip needs considerably fewer molecules for detecting a compound and can be used for analysis of chemical reactions with small drug molecules. Optimizing the thickness of the GO film deposited on the surface of the gold film resulted in a 20% increase in sensitivity of the SPR biosensor. Another important advantage of the new GO based sensor chips is their simplicity and low-cost fabrication compared to sensor chips that are already commercially available.


“BiOptix is pleased that our technology and the expert advice from our team have contributed to such a potentially significant improvement in sensor chip sensitivity,” said Rick Whitcomb, President and CEO of BiOptix.